Acasti Pharma ACST shares are trading higher on Monday after B.Riley FBR upgraded the stock from Neutral to Buy and announced a price target of $2 per share.
Acasti Pharma is a biopharmaceutical innovator advancing a cardiovascular drug, CaPre (omega-3 phospholipid), for the treatment of hypertriglyceridemia, a chronic condition affecting an estimated one third of the U.S. population. The company is focused on addressing a critical market need for an effective, safe and well-absorbing omega-3 therapeutic that can make a positive impact on the blood lipids associated with cardiovascular disease risk.
The company is developing CaPre in a Phase 3 clinical program in patients with severe hypertriglyceridemia
Acasti Pharma shares were trading up 16.74% at 62 cents on Monday. The stock has a 52-week high of $3.08 and a 52-week low of 25 cents.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
